InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
1
T+90 hit rate
67%
T+90 mean return
+1.2%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Izzar Rachid, Responsable de la Maladie d'Alzheimer. Officer active across 1 company, notably BIOGEN INC.. In total, 19 filings have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €256k. History available since 2 December 2021. The latest transaction was filed on 6 February 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations19 total
2,044 shares0Common StockSEC:0000875045-26-000019:0
2,223 shares@ US$135.0046.8% of flowCommon StockSEC:0001127602-25-019295:0
1,515 shares0Common StockSEC:0001127602-25-004452:0
2,043 shares0Common StockSEC:0001127602-25-004243:0
1,370 shares0Common StockSEC:0001127602-24-006216:0
1,515 shares0Common StockSEC:0001127602-24-004794:0
2,043 shares0Common StockSEC:0001127602-24-004308:0
504 shares0Common StockSEC:0001127602-23-020238:0
767 shares0Common StockSEC:0001127602-23-006513:0
1,515 shares0Common StockSEC:0001127602-23-005271:0
1,783 shares0Common StockSEC:0001127602-23-002481:0
1,285 shares0Common StockSEC:0001127602-22-026993:0
570 shares@ US$298.9044.3% of flowCommon StockSEC:0001127602-22-026993:1
425 shares0Common StockSEC:0001127602-22-026993:2
189 shares@ US$298.9014.7% of flowCommon StockSEC:0001127602-22-026993:3
504 shares0Common StockSEC:0001127602-22-019020:0
594 shares0Common StockSEC:0001127602-22-006269:0
351 shares0Common StockSEC:0001127602-22-004988:0
372 shares@ US$228.520.0003% mcap50.0% of flowCommon StockSEC:0001127602-21-030351:0
19 of 19 declarations
About Izzar Rachid
Rachid Izzar is the Head of Alzheimer's Disease at BIOGEN INC. He oversees research and development initiatives related to Alzheimer's disease, working towards advancing treatments and solutions for patients. His expertise in the medical field is essential for guiding the company's efforts in this area.
